Alder Obtains First Milestone Under BMS Deal, Advances Own Program In Cancer Supportive Care
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held biotech earns $15 million as Bristol Myers Squibb readies interleukin-6 inhibitor for Phase IIb dose-ranging trial in rheumatoid arthritis.